Survival signalling by ligand-activated tyrosine kinase receptors plays a crucial role in maintaining the balance between cell viability and apoptosis in multicellular organisms. To identify receptor domains and pathways involved in survival signalling, the nerve growth factor receptor TrkA was expressed in Rat-1/MycER TM ®broblasts. We demonstrate that wt-TrkA receptor delays c-Myc-, U.V.-and Cycloheximide-induced apoptosis and activates targets such as the mitogen-activated protein kinase (MAPK) Erk2 and the serine/threonine kinase Akt/PKB, both of which have been implicated in survival signalling. TrkA mutated within its SHC binding site (Y490F) delays c-Myc-induced apoptosis without activating endogenous Akt/PKB. In contrast, the TrkA Y490F mutant receptor does not delay U.V.-induced apoptosis whilst TrkA mutated at its PLC-g binding site (Y785F) is capable of protecting from apoptosis induced by c-Myc or U.V. treatment. The double mutant TrkA YY490/785FF fails to block either of these two apoptotic stimuli. While PI3-kinase inhibitors LY294002 and Wortmannin competely block survival signalling following U.V. treatment, neither drug aects the ability of TrkA to block c-Myc-induced apoptosis. We show that the Akt/PKB pathway is essential for NGF stimulated TrkA survival signalling in the case of U.V.-induced apoptosis, but that apoptosis induced by c-Myc is also blocked by a novel, Akt/PKB-independent, pathway. These observations suggest that TrkA can activate dierent survival signalling pathways, which can interfere with speci®c apoptotic pathways.
Introduction
Several membrane-bound receptors elicit anti-apoptotic signals upon ligand-induced activation. In comparison to other tyrosine kinase receptors, the ligand-activated IGF-I receptor (IGF-IR) induces the strongest delay of apoptosis in the TM ®broblast cell system (Harrington et al., 1994) . Unfortunately, endogenous expression of IGF-IR in most cell types complicates the analysis of the survival signalling capability of IGF-IR mutants.
To circumvent this problem, we turned to another receptor tyrosine kinase with established anti-apoptotic activity: the high anity nerve growth factor (NGF) receptor TrkA. Because TrkA is not expressed in ®broblasts, there is no interference due to endogenous receptor activity in such cells. Furthermore, TrkA contains only two tyrosine residues outside its catalytic domain which are phosphorylated upon ligand binding. This constitutes a relatively simple receptor/cell system for studying survival signalling when compared with other receptors implicated in cell survival, such as PDGF or IGF-I receptors. Accordingly, we expressed wt-or mutant-TrkA receptors in Rat-1 ®broblasts and assayed their abilities to confer NGF-dependent suppression of apoptosis induced by various triggers: speci®cally, activation of the c-Myc protein in low serum and U.V.-irradiation.
The anti-apoptotic activity of TrkA has been established in nerve cells. NGF-activated TrkA receptor rescues serum-deprived PC12 cells from apoptosis (Yao and Cooper, 1995) . Furthermore, TrkA knock-out mice show a 70 ± 90% reduction in the number of trigeminal neurones and similar losses in the sympathetic and dorsal root ganglia, probably due to a lack of survival signals resulting in a variety of sensory defects at P10. At P20 half of TrkA-de®cient mice are dead (Smeyne et al., 1994) .
The biochemical pathways responsible for the NGF/ TrkA survival activity are not well de®ned. However, two signalling pathways have recently been implicated in survival signalling by tyrosine kinase receptors: the classic Raf/MAPK pathway in the PC12 cell system (Xia et al., 1995) and the PI3-kinase pathway in PC12 cells and in ®broblasts Cooper, 1995, 1996) . Both, the MAPK and the PI3-kinase pathways seem to be required for IGF-I to inhibit apoptosis of dierentiated PC12 cells following NGF withdrawal (Parrizas et al., 1997 ). An anti-apoptotic role of PI3-kinase is further supported by the ®nding that the PI3-kinase-activated serine/threonine kinase Akt/PKB is required for IGF-Iinduced survival of serum-deprived neurones (Dudek et al., 1997) and by the observation that activated Akt/ PKB is sucient to block U.V.-induced apoptosis in ®broblasts (Kulik et al., 1997) . Furthermore, activated forms of both PI3-kinase and Akt/PKB suppress c-Myc induced apoptosis in Rat-1MycER TM cells when overexpressed (Kaumann-Zeh et al., 1997) .
Results
TrkA protects against c-Myc, U.V. and cycloheximide induced apoptosis
In this study we have generated Rat-1 cell lines coexpressing wt-or mutated human TrkA receptors together with the conditional Myc/estrogen receptor fusion protein MycER TM (Littlewood et al., 1995) . The human TrkA cDNA was stably expressed in Rat1MycER TM cells using the expression vector pMEX-neo (Martin-Zanca et al., 1989) . Expression of the 140 and 110 kDa TrkA proteins was monitored by immunoprecipitation with the TrkA-speci®c monoclonal antibody MGR12 (Cabrera et al., 1996) followed by Western blot analysis using a pan-Trk antibody (anti-203; Martin-Zanca et al., 1989) . Tyrosine phosphorylation of TrkA was readily detectable in these cells after 5 min of NGF treatment. Cell lines expressing comparable levels of wt-and mutant-TrkA receptors, as assessed by Western blot and¯ow cytometric analyses, were used for this study (Figures 1a and 3b) .
To or treatment with cycloheximide (50 mg/ml), we observed 80% apoptosis after 20 h (Figure 1b, c, d, respectively) . Addition of NGF (we routinely used 100 ng/ml, but lower concentrations were also eective) to MycER TM /TrkA ®broblasts resulted in a substantial delay of apoptosis induced by MycER TM or U.V. The delay was comparable to the survival aorded by IGF-I mediated activation of endogenous IGF-IR in the same cell lines (data not shown). Wt-TrkA also elicited good protection against apoptosis induced by cycloheximide, indicating that de novo protein synthesis is not required for TrkA-mediated suppression of apoptosis. No NGF-dependent protection was afforded by expression of comparable levels of a kinase-defective TrkA mutant indicating a requirement for receptor tyrosine kinase activity.
TrkA activates the MPAK Erk2, S6-kinase and Akt/PKB in Rat-1 ®broblasts A role for the Raf/MAPK pathway in promoting cell survival is suggested by studies on PC12 phaeochromocytoma cells, in which selective activation of the Erk-MAP-kinases prevents cell death and suppresses the SAPK and p38 pathways. Concurrent activation of SAPK or p38 together with inhibition of Erks seem to be necessary for apoptosis following NGF withdrawal (Xia et al., 1995 (Figure 2a, upper panel) .
The PI3-kinase pathway has also recently been implicated in survival signalling in PC12 cells and ®broblasts Cooper, 1995, 1996) . Moreover, overexpression of constitutively active forms of the PI3-kinase target Akt/PKB has been shown to be sucient to block apoptosis in a number of cell types (Dudek et al., 1997; Kulik et al., 1997; KaumannZeh et al., 1997; Khwaja et al., 1997) . NGFstimulated TrkA activates PI3-kinase in both PC12 cells and in ®broblasts expressing TrkA (Carter and Downes, 1992; Raoni and Bradshaw, 1992; Solto et al., 1992; Ohmichi et al., 1992) . Association of PI3-kinase with the TrkA receptor has been detected both in vitro and by co-immunoprecipitation in NIH3T3 and PC12 cells overexpressing TrkA (Solto et al., 1992; Obermeier et al., 1993b) , although not in normal NGF-stimulated PC12 cells (Ohmichi et al., 1992) . Earlier in vitro studies suggested that the p85 subunit of PI3-kinase associates with NGF-stimulated TrkA through tyrosine residue Y751 (Obermeier et al., 1993b) . However, recent studies using mutant TrkA receptors indicate that the activation of PI3-kinase depends in the main on phosphorylation of tyrosine Y490, the SHC binding site in human TrkA (Baxter et al., 1995) .
The PI3-kinase targets S6-kinase (Weng et al., 1995) and Akt/PKB (Burgering and Coer, 1995; Franke et al., 1995) Figure 2b , respectively). As controls for Akt/PKB activation we stimulated cells with EGF (100 ng/ml) or PDGF-AB (50 ng/ml); both of which bound to endogenous receptors in ®broblasts and activated Akt/PKB. As expected, activation of Akt/PKB (and S6-kinase) was blocked by the PI3-kinase inhibitors LY294002 (Vlahos et al., 1994) and Wortmanin (Thelen et al., 1994) . However, we found LY294002 to be a more eective and stable inhibitor, therefore it was preferentially used in this study (Figure 2a, lower panel and 2b) .
TrkA Y490F signals survival without activating Akt/PKB To further investigate the contributions to TrkA survival signalling of the various signalling pathways activated by TrkA, we used a set of mutants targeted to TrkA auto-phosphorylation sites. Tyrosine residues Y670, Y674 and Y675 residing within the receptor activation loop' are not only important for the intrinsic activity of the receptor but regulate the phosphorylation of the two tyrosine residues outside the catalytic domain, Y490 and Y785, therefore controlling speci®c signalling pathways (Mitra, 1991; Cunningham et al., 1997) . Although the autophosphorylation of these`activation loop' residues should play a role in TrkA survival signalling it is not sucient to elicit an anti-apoptotic eect because TrkA receptors mutated only at the two tyrosines outside the kinase domain (TrkA YY490/785FF) did not show any survival response. Therefore we concentrated in this study on TrkA receptors mutated at tyrosine residues Y490 or Y785 which are strongly auto-phosphorylated upon NGF binding to the wtreceptor. One of these, phosphotyrosine Y490, binds SHC proteins of 48 kD, 53 kD and, to a lesser extent, 68 kD. SHC proteins are thought to associate with Grb2 or Ras-GAP, both of which modulate p21 ras activity (Stephens et al., 1994) . The other autophosphorylation site, tyrosine Y785, mediates association with and tyrosine phosphorylation of PLC-g (Obermeier et al., 1993a) . A known target for PLC-g activity is phosphatidylinositol-4,5-bisphosphate (PI-4,5-P 2 ) which is cleaved by PLC-g to yield diacylglycerol and inositol trisphosphate. These two second messengers, respectively, activate protein kinase C (PKC) and trigger a rise in intracellular calcium. Nontheless, TrkA mutants with mutations in either the SHC binding site (Y490F) or the PLC-g binding site (Y785F) each still dealy MycER TM induced apoptosis as eciently as the wt-receptor (Figure 3a , left and right panel, respectively). In contrast, a TrkA receptor mutated at both these sites (YY490/785FF) looses all its survival signalling capacity (data not shown).
Similarly to the observation made for IGF-IR signalling in Rat-1 cells by Kulik et al. (1997) , the MAPK inhibitor PD098059 had no eect on survival signalling of wt-TrkA against MycER TM or U.V.-induced apoptosis in our cell-system (data not shown). These data are consistent with the fact that NGF induced survival in primary sympathetic neurones is not blocked by PD098059 (Creedon et al., 1996; Virdee and Tolkovsky, 1996) suggesting that ± at least in the cell systems mentioned above ± MAPK does not add to the survival signals of IGF-IR or TrkA. This is in contrast with the reported requirement of MAPK activation for IGF-I survival signalling in PC12 cells (Parrizas et al., 1997) .
Furthermore, the S6-kinase inhibitor Rapamycin (100 ng/ml) exerted no eect on TrkA survival signalling, indicating that S6-kinase is also not required for TrkA anti-apoptotic activity in our cell system (data not shown).
Given the documented role of Akt/PKB in survival signalling, we were surprised to ®nd that TrkA Y490F (SHC binding site mutant), retains full ability to confer NGF-induced protection against apoptosis induced by MycER TM , even though it has no detectable activating eect on endogenous Akt/PKB (Figure 3c ). This result was con®rmed using two independent stable cell lines, one of which (C7) expresses equal and the other (C11) expressing higher levels of TrkA Y490F protein compared to the wt-TrkA clone (G3) (Figure 3b and  c) . In contrast to TrkA Y490F, TrkA Y785F eectively activates Akt/PKB, con®rming earlier reports, indicating that residue Y490 drives PI3-kinase activation by NGF-stimulated TrkA (Baxter et al., 1995) ; Figure 3c The phosphorylation and expression levels of the TrkA mutant clones C7, C11 (both Y490F) and of clone B30 (Y785F) were monitored as described in Materials and methods. Clone C7 expresses levels of TrkA Y490F comparable to those of the wt-clone G3, whereas clones C11 and B30 express about four times higher receptor levels than clone C7. NGF stimulation of both, clone C7 and C11 block MycER TM -induced apoptosis. (c) In vitro kinase assay performed on immunoprecipitated Akt/PKB proteins using histone H2B as substrate. Both clone C7 and C11 fail to activate Akt/PKB upon NGF addition, while PDGF-AB stimulation results in both clones in activation of Akt/PKB. TrkA Y785F can still activate Akt/PKB upon addition of NGF or PDGF-AB, and is also capable of NGF-induced anti-apoptotic activity against MycER
TM -triggered cell death
TrkA signalling and apoptosis E Ulrich et al is further supported by studies using the PI3-kinase inhibitor LY294002. By inhibiting PI3-kinase, LY294002 also eectively blocks Akt/PKB activation ( Figure 2b ). The observation that LY294002 by itself induces apoptosis in serum starved ®broblasts (Yao and Cooper, 1996) and Figure 4a , open squares) may lead to the idea that survival pathways are, in general, PI3-kinase dependent. Surprisingly, apoptosis induced by MycER TM alone, or in the presence of LY294002, is blocked by NGF-activated wt-TrkA, TrkA Y490F or TrkA Y785F receptors (Figure 4a, black squares) . These observations suggest that TrkA is capable of triggering an additional, PI3-kinase independent signalling pathway that promotes cell survival. Although over-expression of activated Akt/PKB in ®broblasts is sucient to delay MycER TM induced death (Kaufmann-Zeh et al., 1997), this newly uncovered Akt/PKB independent pathway is capable of blocking apoptosis induced by MycER TM alone or together with LY294002, indicating that Akt/PKB activation is not necessary to block Myc-induced death in this cell system (see also Figures 2b and 3c) .
A very dierent situation was found when apoptosis was induced by U.V.-irradiation. Whereas either wtTrkA or TrkA Y785F eectively delayed U.V.-induced apoptosis, TrkA Y490F did not protect cells against U.V.-induced death. This suggests that full Akt/PKB activation is required for suppression of U.V.-induced apoptosis. This idea is further supported by the fact that the PI3-kinase inhibitor LY294002, which prevents activation of endogenous Akt/PKB, completely inhibits the ability of wt-TrkA and TrkA Y785F to suppress U.V.-induced apoptosis (Figure 4b) .
Furthermore, LY294002 sensitizes Rat-1 ®broblasts to U.V.-induced apoptosis (Figure 4b , black squares), perhaps because it inhibits an endogenous basal PI3-kinase activity. This phenomenon may be similar to the reported enhanced sensitivity to X-ray induced death elicited by Wortmannin in murine ®broblasts and human tumor cells (Price and Youmell, 1996) . 
Discussion
The signalling pathways used by the NGF-stimulated TrkA receptor have been the focus of research of many groups in the last few years. The receptor domains and target molecules involved in the dierent biological activities of TrkA have been de®ned, with special emphasis on the pathways required for neuronal dierentiation (see Greene and Kaplan, 1995; Kaplan and Miller, 1997 for review) .
In this work we have concentrated in de®ning the survival signalling pathways used by ligand-activated TrkA receptors to block ®broblast cell death triggered by speci®c apoptotic stimuli.
The data presented here lead us to the model depicted in Figure 5 . We propose that TrkA can activate at least two independent survival pathways: Phosphorylation of tyrosine residue Y490 (SHC binding site in TrkA) triggers a PI3-kinase4Akt/ PKB-dependent pathway which is required for TrkAmediated survival against U.V.-induced apoptosis. Protection from U.V.-irradiation is blocked by the PI3-kinase inhibitors Wortmannin and LY294002, and mutation at this site (Y490F) abolishes the TrkA survival response against U.V.-induced death. This PI3-kinase4Akt/PKB pathway may also participate in suppression of c-Myc-induced apoptosis. Another pathway also initiated at tyrosine Y490, but independent of PI3-kinase activity, is capable of blocking cMyc, but not U.V.-induced apoptosis.
Phosphorylation of tyrosine residue Y785 (PLC-g binding site) triggers a survival pathway which may or may not be identical to the second one activated by Y490. This pathway blocks c-Myc-induced apoptosis in a PI3-kinase-independent manner, but fails to suppress U.V.-induced death. The biochemical events initiated with the phosphorylation of residue Y785 leading to survival signalling are unknown and will be the focus of further research.
The ability of ligand activated TrkA receptor to use dierent survival signalling pathways to block apoptosis triggered by dierent stimuli may be a unique feature of this receptor. There are, however, several cell types in which dierent growth factors and cytokines acting through speci®c receptors use dierent signalling pathways to block cell death triggered by a particular stimulus. For example, IL-3 dependent myeloid progenitor cells can be maintained alive both by IL-3 and by IGF-I. Survival signalling by IGF-I requires PI3-kinase activation, whereas IL-3 does not (Minshall et al., 1996) . Survival of the mast cell line MC-9 elicited by IL-4, IL-3 or Steel Factor is blocked by Wortmannin or LY294002. In contrast, these drugs do not inhibit GM-CSF-mediated survival in MC-9 cells, in spite of the fact that this factor uses signalling pathways similar to those used by IL-3 (Scheid et al., 1995) . These examples demonstrate that the same receptor (IL-3 Receptor) is able to use PI3-kinase dependent or independent survival pathways depending on the cellular context. In an analogous way, the TrkA receptor requires PI3-kinase activity to suppress death of serum-deprived PC12 cells, but not to block Mycinduced apoptosis in Rat-1 ®broblasts. A dierent model is provided by cerebellar granule cells which can be maintained alive in serum with high K + -ion concentrations. Lowering this concentration of K + results in rapid apoptotic death, which can be prevented by IGF-I in a PI3-kinase-dependent manner. Interestingly, elevated K + levels do not activate PI3-kinase and elicit neuronal survival in the presence of PI3-kinase inhibitors (D'Mello et al., 1997) . In these cells, PI3-kinase activation of the serine/ threonine kinase Akt/PKB is necessary for IGF-Iinduced survival but not for the anti-apoptotic eect of K + -ions (Dudek et al., 1997) . A further example of PI3-kinase-independent survival signalling ± with some similarity to that of TrkA ± has been observed in primary bone marrow-derived mast cells, which are dependent of CSF-I for survival. C-Kit/CSF-I receptors mutated at residue Y719 have lost their ability for ligand-dependent PI3-kinase activation without losing c-Kit-mediated survival of primary bone marrow-derived mast cells, thus indicating that PI3-kinase activity is not necessary for survival signalling in these cells. However, mutating residue Y821 (Y821F) abolishes survival without aecting the ligand-induced activation of PI3-kinase, Ras and MAPK, indicating that these pathways are not sucient for survival signalling (Serve et al., 1995) . These results also suggest that residue Y821 is involved in triggering a survival pathway that is independent of PI3-kinase activation. By analogy, residue Y785 of TrkA seems to be able to stimulate a survival pathway capable of blocking Myc-induced apoptosis, which does not require PI3-kinase activation; however, the pathway to suppress U.V.-induced death initiates at TM -induced apoptosis in a PI3-kinase-independent manner (i.e. is not inhibited by LY294002). Phosphorylation of tyrosine Y785, at the PLC-g binding site, also activates a PI3-Kinase-independent survival pathway which delays MycER TMinduced apoptosis but not U.V.-induced death residue Y490, and is PI3-kinase dependent. Another NGF-driven survival pathway that requires the activation of PI3-kinase is the suppression of peroxynitrite-triggered apoptosis, which is also abolished by PI3-kinase inhibitors (Spear et al., 1997) . Finally, NGF suppresses the formation of reactive oxygen species (ROS) following NGF withdrawal and other neuronal insults by a MAPK-dependent pathway (Dugan et al., 1997) . These observations, taken together with the PI3-kinase independent TrkA survival pathways described in the present study, lead to the conclusion that PI3-kinase4Akt/PKB activation may not be necessary or sucient to mediate speci®c NGF-induced survival responses.
Our results are in apparent contradiction to those of Cooper (1995, 1996) , establishing an obligatory role for PI3-kinase in NGF-stimulated survival. It is possible that these contradictory results are due to the dierent apoptotic stimuli that have been analysed. Following this view, anti-apoptotic signalling might be far more complex than previously envisioned, requiring dierent survival pathways in response to dierent apoptotic stimuli.
Independent survival pathways that block apoptosis in a more speci®c, inducing-agent-dependent way suggest the exciting possibility of an additional complexity level in regulating apoptosis. In the skin, for instance, epidermal keratinocytes become rapidly apoptotic following environmental U.V. doses while melanocytes appear to be resistant to the same doses (Young, 1987) . Melanocytes express NFG receptors (Yaar et al., 1994) and it has been shown that NGF, which is constitutively produced by keratinocytes and further induced by U.V.-irradiation, protects melanocytes from U.V.-induced apoptosis (Zhai et al., 1996) . According to the data discussed above we predict that short term protection against U.V.-induced depletion of these minimally proliferating melanocytes is mediated by an Akt/PKB dependent pathway. For long term survival these cells may be protected by other means such as Bcl-2 up-regulation (Zhai et al., 1996) . Because cells protected against irradiation are doomed to accumulate mutations leading to the malignant activation of oncogenes, such a survival pathway would increase the possibility to develop cancer. Survival pathways controlling apoptosis caused by such oncogenes should be strongly down-regulated in melanocytes, as a natural mechanism for protection against this increased risk of tumour development.
The activation or downregulation of distinct survival pathways targeting dierent apoptotic pathways might be of great importance in`®ne tuning' the survival chances of a speci®c cell-type within its tissue environment. Understanding the biochemical differences of the diverse pathways signalling death or survival may be of practical importance for the control of pathological conditions in which an unbalance between cell survival and apoptosis occurs.
Materials and methods

Generation of cell lines
TrkA mutants were generated by site-directed mutagenesis as described (Kunkel et al., 1987) , using a cDNA encoding the human wt-TrkA as template (Martin-Zanca et al., 1989). cDNAs encoding the full length wt-TrkA receptor, or the single-site mutants (Y490F, Y785F) were expressed using the pMEX-neo expression vector (Martin-Zanca et al., 1989) . The kinase-inactive mutant (K538A) was expressed from a pCMV5-based expression vector (a gift from Dr Moses Chao, Cornell University, NY), and the double mutant (Y490/785F) from a pLNCX-5-derived expression vector (a gift from Dr David Kaplan, McGill University, Montreal). Stable cell lines co-expressing wildtype and mutant TrkA receptors, together with a conditional MycER TM fusion protein were generated by transfection of Rat-1MycER TM cells (Littlewood et al., 1995) with the above described expression vectors, following the calcium phosphate precipitation technique. After G418 selection (350 mg/ml of active antibiotic) individual colonies were isolated by ring cloning and expanded as cell lines.
TrkA expression and activation
TrkA expression was analysed by immunoprecipitation using a monoclonal antibody speci®c for human TrkA (MGR12; Cabrera et al., 1996) followed by Western blotting using a pan-Trk antibody (anti-203) raised against a synthetic peptide corresponding to the 14 carboxy-terminal aminoacid residues in human TrkA (Martin-Zanca et al., 1989) . NGF-induced TrkA phosphorylation was analysed after treating the cells with 100 ng/ml of NGF, at 378C, in serum-free medium. 650 mg of total cell protein were immunoprecipitated with anti-203 antiserum, resolved in 10% SDS ± PAGE gels, and transferred to Immobilon-P membranes. Filters were then blocked and incubated with the anti-phosphotyrosine monoclonal antibody 4G10 (Upstate Biotechnology Inc.). Bound antibodies were visualised by ECL (Amersham).
Induction and analysis of apoptosis
Rat-1 cells co-expressing MycER TM and TrkA were serumdeprived for 48 h. MycER TM -induced apoptosis was triggered by addition of 4-hydroxytamoxiphen (4-OHT; 100 nM). For U.V.-induced apoptosis cells were covered with 3 ml of PBS on a 5 cm dish, U.V.-irradiated (about 40 J/m 2 ) and then incubated in serum free medium. Immediately after 4-OHT or U.V. treatment, NGF (100 ng/ml) was added. In the case of cycloheximide treatment (50 mg/ml) NGF was added 1 h after the drug. Apoptosis was analysed by time-lapse videomicroscopy and by FACS (sub-G1 DNA containing cells; Darzynkiewicz et al., 1992) in at least two independent cell lines expressing wt-or mutant-TrkA receptors. Experiments were repeated at least four times.
Erk2 and S6-kinase phosphorylation
Equal numbers of cells were serum starved for 48 h and induced with serum (10%), NGF (100 ng/ml) or EGF (100 ng/ml) for 10 min. Erk2 phosphorylation was determined by mobility shift of p42 MAP-kinase to its phosphorylated pp42 form on a 15% low bis-acrylamide gel. Western immunoblotting was performed using antiErk2 antibody (Anti-MAPK (Erk2), monoclonal, Upstate Biotechnology). S6-kinase phosphorylation was tested in an analogous way using anti-S6-kinase antibody (p70 S6Kinase (C18), Santa Cruz Biotechnology).
Akt/PKB assays
Akt/PKB in vitro kinase assays were performed by immunoprecipitating (Anti-Human-Rac-CT; Upstate Biotechnology) endogenous Akt/PKB from equal numbers of cells after 10 min NGF (100 ng/ml), EGF (100 ng/ml), or PDGF-AB (50 ng/ml) induction of serum starved Rat1MycER TM TrkA cells. Treatment of cells for 1 min with LY294002 (10 mM) prior to NGF addition was used to block Akt/PKB activation. Histone H2B (BoehringerMannheim) was used as substrate. Proteins were separated on a 15% SDS ± PAGE gel, blotted and exposed.
